Agilent Technologies Introduces High-Capacity Human-14 Protein Removal System for Proteomic Biomarker Discovery

Agilent Technologies Inc. has introduced a version of its Multiple Affinity Removal System (MARS), the Human-14, which removes 95 percent to 99 percent of the 14 most abundant proteins from human blood serum and plasma in one easy step.

These high-abundance proteins account for 94 percent of the total protein mass, and removing them facilitates the discovery and identification of low-abundance proteins that may be biomarkers for a wide range of diseases.

Proteins associated with diseases are typically present in small amounts in human serum and may be difficult to isolate amid high-abundance proteins, such as albumin and immunoglobulin G. By reducing by half the number of proteins masking potential biomarkers, the new Agilent Human-14 products help researchers delve more deeply into the human proteome and advance the progress of proteomic research.

The MARS Hu-14 joins Agilent’s successful line of protein fractionation products. The family includes: the MARS Human-7, MARS Human-6HC, MARS Human-6, and MARS Mouse-3 columns and spin cartridges.

The Agilent MARS Hu-14 is available in both HPLC column and spin cartridge formats, facilitating protein removal through liquid chromatography or centrifugation techniques. The high-capacity products can be used for more than 200 runs, allowing immunodepletion of more than 8,000 microliters of serum or plasma using a single standard column format.